Matches in Wikidata for { <http://www.wikidata.org/entity/Q92759790> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- Q92759790 description "article scientifique publié en 2019" @default.
- Q92759790 description "artículu científicu espublizáu en mayu de 2019" @default.
- Q92759790 description "scientific article published on 17 May 2019" @default.
- Q92759790 description "wetenschappelijk artikel" @default.
- Q92759790 description "наукова стаття, опублікована 17 травня 2019" @default.
- Q92759790 name "Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia" @default.
- Q92759790 name "Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia" @default.
- Q92759790 type Item @default.
- Q92759790 label "Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia" @default.
- Q92759790 label "Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia" @default.
- Q92759790 prefLabel "Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia" @default.
- Q92759790 prefLabel "Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia" @default.
- Q92759790 P1433 Q92759790-1C00659C-0778-417F-B159-0562CCE94701 @default.
- Q92759790 P1476 Q92759790-B6A4FB27-1FC3-48E2-BD41-A3A5C1EA7715 @default.
- Q92759790 P2093 Q92759790-078622D0-A474-45BC-8988-EC9C8BF7046B @default.
- Q92759790 P2093 Q92759790-0A890BA4-34B8-451E-8B95-97F2E46CDC7C @default.
- Q92759790 P2093 Q92759790-3302ACFB-9651-44C9-8D3F-45D929C5367B @default.
- Q92759790 P2093 Q92759790-61D83124-BA19-4652-A713-6A1086E29347 @default.
- Q92759790 P2093 Q92759790-681CEBD4-3867-4667-AEC6-27288B13CA62 @default.
- Q92759790 P2093 Q92759790-7000643B-B13E-4C04-98C6-1809075E6753 @default.
- Q92759790 P2093 Q92759790-7F1CDECA-47AC-4D5C-8EB4-BBE0A035029F @default.
- Q92759790 P2093 Q92759790-8E8243DD-F752-4333-AD1B-74D0FE6A98E7 @default.
- Q92759790 P2093 Q92759790-A9FD8ADA-3DDA-438F-B9A0-6F96F5ECB611 @default.
- Q92759790 P2093 Q92759790-BDEADB36-5521-4A59-869B-1E6E3A778274 @default.
- Q92759790 P2093 Q92759790-CD4D2BCE-6E0A-4B94-B2CD-C0D33B7EE37A @default.
- Q92759790 P2093 Q92759790-E513D2AA-3CA1-49F0-BC66-EAA0251426AE @default.
- Q92759790 P2093 Q92759790-E8A0A2BA-515E-4A8A-9CA7-F71CF0F03AC0 @default.
- Q92759790 P2093 Q92759790-E985AAAE-C594-42F9-9D34-EF3987E706FC @default.
- Q92759790 P2093 Q92759790-F959D6B2-69F5-45BD-8594-BFDB72570B9D @default.
- Q92759790 P304 Q92759790-B1DA2E00-6C30-48ED-BC73-D5BED55E7E49 @default.
- Q92759790 P31 Q92759790-FA6D39DC-B186-4647-A9B6-8C7D94646123 @default.
- Q92759790 P356 Q92759790-99139F33-8E8C-47AA-8D91-3CA396D5B01D @default.
- Q92759790 P433 Q92759790-93ABED4A-18AE-4DEE-A6E3-05A4612BD8B4 @default.
- Q92759790 P478 Q92759790-A86AD244-BF2B-498F-9BF3-3F8B6F25FD5E @default.
- Q92759790 P50 Q92759790-1871387C-9009-4A8D-A964-C54D14EF235B @default.
- Q92759790 P577 Q92759790-8795B586-C2D7-4F7D-9FEC-D5D125BD867F @default.
- Q92759790 P698 Q92759790-2B8A2579-46C8-4AA4-B721-0648AC3CA2C0 @default.
- Q92759790 P921 Q92759790-17F3447D-BA9D-4A96-91C9-4618782C8EE9 @default.
- Q92759790 P921 Q92759790-AD1546B9-1D0B-4F01-9EC3-FBCEF43DD21F @default.
- Q92759790 P921 Q92759790-B574EE5B-D5A3-454B-AAE0-547634661E9B @default.
- Q92759790 P356 J.CLML.2019.05.001 @default.
- Q92759790 P698 31201134 @default.
- Q92759790 P1433 Q5133774 @default.
- Q92759790 P1476 "Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia" @default.
- Q92759790 P2093 "Behrang Amini" @default.
- Q92759790 P2093 "Chutima Kunacheewa" @default.
- Q92759790 P2093 "Donna M Weber" @default.
- Q92759790 P2093 "Elisabet E Manasanch" @default.
- Q92759790 P2093 "Hans C Lee" @default.
- Q92759790 P2093 "Krina K Patel" @default.
- Q92759790 P2093 "Lei Feng" @default.
- Q92759790 P2093 "Muzzaffar H Qazilbash" @default.
- Q92759790 P2093 "Qaiser Bashir" @default.
- Q92759790 P2093 "Rajit Nair" @default.
- Q92759790 P2093 "Raymond Alexanian" @default.
- Q92759790 P2093 "Rohtesh S Mehta" @default.
- Q92759790 P2093 "Sairah Ahmed" @default.
- Q92759790 P2093 "Samer Tabchi" @default.
- Q92759790 P2093 "Sheeba K Thomas" @default.
- Q92759790 P304 "560-569" @default.
- Q92759790 P31 Q13442814 @default.
- Q92759790 P356 "10.1016/J.CLML.2019.05.001" @default.
- Q92759790 P433 "9" @default.
- Q92759790 P478 "19" @default.
- Q92759790 P50 Q91428664 @default.
- Q92759790 P577 "2019-05-17T00:00:00Z" @default.
- Q92759790 P698 "31201134" @default.
- Q92759790 P921 Q18936 @default.
- Q92759790 P921 Q422252 @default.
- Q92759790 P921 Q7201765 @default.